DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)

NEWS RELEASE:

DIGITAL LIFE LINE PTE. LTD. ANNOUNCES THE CLINICAL DEPLOYMENT OF AUTOMATED VISUAL ACUITY TEST DEVICES AT A HOSPITAL OPHTHALMOLOGY CLINIC IN SINGAPORE, A GROUNDBREAKING INNOVATION THAT WILL RESHAPE THE LANDSCAPE OF OPHTHALMOLOGY

SINGAPORE – 20 January 2025 — DISA Limited (the "**Company**", and together with its subsidiaries, the "**Group**"), is pleased to share that Digital Life Line Pte. Ltd. ("**DLL**"), a subsidiary of DiSa Digital Safety Pte. Ltd. that is a wholly owned subsidiary of the Company, is thrilled to announce the it has received the letter of award from one of the major public hospitals in Singapore, and has signed the letter of acknowledgement and the relevant contract today, for the clinical deployment of its Automated Visual Acuity Test ("**AVAT**") devices at a hospital ophthalmology clinic in Singapore from 3 February 2025 to 2 February 2026, providing accurate visual acuity ("**VA**") testing that can be performed by patients themselves without supervision within a tabletop footprint.

This marks the first commercial deployment of AVAT in Singapore. Under the contract, DLL will supply AVAT on a leasing basis, charging a fixed monthly rental fee along with a per-test fee, creating a hybrid pricing structure. This approach ensures a steady revenue stream through the fixed rental while allowing for scalability based on usage.

DLL has also received CE mark for its AVAT under Article 27 and 29 of the Regulation (European Union ("**EU**")) 2017/745 (Medical Device Regulation) or Article 26 of Regulation (EU) 2017/746 (In-Vitro Diagnostic Regulation) on 16 January 2025. CE marking is a certification that indicates that a product complies with the EU health, safety, and environmental protection requirements. CE marking is also a declaration by the manufacturer or importer that a product has undergone the necessary testing and verification to comply with the applicable EU directives and is required for products manufactured anywhere in the world that are marketed within the EU.

This milestone follows a 2-month-long pilot study at the Department of Ophthalmology of a public hospital that assesses the accuracy, usability and patient satisfaction of AVAT, and represents a landmark in digitalizing the process of VA testing as AI-enabled medical devices continue to drive greater impact in the medical industry.

AVAT is the result of several years of dedicated research and development work by the Department of Ophthalmology at the National University Hospital ("**NUH**") and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore ("**NUS Medicine**") to alleviate operational challenges with VA testing.

DLL is privileged to commercialize this innovation, having received Class A Medical Device Registration for AVAT from the Health Science Authority (HSA) Singapore in August 2023.



Associate Professor Victor Koh, Head, Department of Ophthalmology at NUH and NUS Medicine shared: *"The successful trial deployment of scalable technologies like the AVAT is a step towards enhancing patients' accessibility to innovative medical solutions, leading to enhanced patient care and improved clinical outcomes.*

With the rising prevalence of eye ailments, we look forward to exploring more collaborations with industry partners such as Digital Life Line, in developing and pioneering technologies that will better identify, diagnose and treat such conditions in our patient community. As an academic healthcare institution, such technologies represent our commitment to translational research work, aimed at advancing preventive care while lowering patient costs and manpower resources."

Current vision screening devices require the use of large spaces and need to be supervised by trained nurses, limiting testing productivity and creating long wait-times. VA testing is one of the most common stations in the eye clinic, as it is required of most patients. However, VA testing requires a 6-meter space and trained staff for each test, which often creates huge bottlenecks in the clinical workflow. As the number of patients seeking medical care for vision impairment increases due to ageing population, there is an urgent need for existing healthcare infrastructure to scale up capacity to meet this demand. This is where technology-enabled medical devices like AVAT can be critical force multipliers.

By incorporating a familiar number pad input with audio confirmation, the key goal of AVAT is to allow self-testing of VA by patients with minimal or no supervision, which frees up healthcare workers to focus on other core tasks. AVAT also utilizes proprietary afocal optics system to recapitulate the current 6-meter test in 0.5 meter, which rules out effects of positioning variation on test outcomes that may apply to VA tests that attempts to do so within a smaller footprint. Its adaptive testing format ensures accurate VA testing and capitulates the existing VA testing workflow, even the pinhole testing that is triggered automatically when the VA result fails a defined threshold. It is this unique combination of hardware and software advantages that positions AVAT favorably as part of the next generation of vision screening devices.

AVAT testing workflow:



In the study conducted in September 2023 with 365 patients (of which 32% were above the age of 60), the VA scores of AVAT and the manual test method were highly correlated, achieving Pearson's correlation above 0.9. Based on the criteria of VA 6/12 or worse which is used to determine additional testing with a pinhole occluder, AVAT correctly identified 163 of 168 patients, representing 97% sensitivity. In a follow-up satisfaction survey, 81.6% of patients expressed preference for AVAT over the manual test method.

Comparison of DLL's AVAT device against other VA devices in the market:

Market comparision: Existing VA devices can be categoried into: a) Printed VA charts, b) VA chart projectors, c) LCD screens, d) Standalone devices

	 Printed VA charts	 VA chart projectors	 LCD screens	 Standalone devices	 **Automated Visual Acuity Test (AVAT)**
Afocal optical system	No	No	No	No	Yes
Adaptive testing process based on patient input	No	No	No	No	Yes
Customisatio (VA charts, testing workflow)	No	No	No	No	Yes
Self-testing with minimal/no supervision	No	No	No	Yes	Yes
Does not require trained staff	No	No	No	Yes	Yes
Fits on table-top (<1m)	No (requires 2.5-6m)	No (requires 2.5-6m)	No (requires 2.5-6m)	Yes	Yes
Possibility to integrate with electronic medical record systems	No	No	No	No (result not given as standard VA format 6/X)	Yes

Mr. Eddie Chng, the Managing Director and CEO of DLL, said *"We are truly honoured to be given the opportunity to deploy AVAT in Singapore. Due to the convenience and reduced manpower needs, self-administered kiosks are becoming common, ranging from supermarket self-checkout machines to home-based blood pressure monitoring devices. AVAT enables the patient to manage and test their own visual acuity in a 0.5-meter footprint, which frees up the nurses for more critical tasks. We know that loss of eyesight is irreversible, so the widespread deployment of devices like AVAT in the community is key not only for early diagnosis and intervention, but also to alleviate the workload at tertiary hospitals facing severe manpower shortages."*

Moving forward, DLL will continue to work with other public and private eye specialist centres to offer AVAT as a scalable solution for accurate, accessible vision screening across Singapore and then globally. At the same time, DLL is progressively rolling out other devices to provide a comprehensive suite of tests that can be digitalized into electronic medical records and telemedicine.

----------End----------

About DISA Limited *(SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)*

DISA Limited, is a publicly traded company on the Singapore Catalist Stock Exchange. Together with our subsidiaries, the Group focuses on pioneering and adopting the latest technology innovations to enhance outcomes, reduce costs, improve efficiencies within the healthcare and consumer industry.

Bringing scaled solutions that thrive in a changing world, we leverage on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalization of product and services that optimizes efficiency and quality standards in our targeted markets.

More information is available at www.disa.sg.

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited
Address: 1 Robinson Road, #21-01 AIA Tower, Singapore 048542
Telephone number: +65 6232 3210